AU2009279667A1 - Novel methylenedioxy phenolic compounds and their use to treat disease - Google Patents

Info

Publication number

AU2009279667A1

AU2009279667A1 AU2009279667A AU2009279667A AU2009279667A1 AU 2009279667 A1 AU2009279667 A1 AU 2009279667A1 AU 2009279667 A AU2009279667 A AU 2009279667A AU 2009279667 A AU2009279667 A AU 2009279667A AU 2009279667 A1 AU2009279667 A1 AU 2009279667A1

Authority

AU

Australia

Prior art keywords

inv

compound

methylenedioxy

group

acid

Prior art date

2008-08-05

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• Discuss

• -1 methylenedioxy phenolic compounds Chemical class 0.000 title claims description 114
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 15
• 201000010099 disease Diseases 0.000 title description 8
• AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 122
• 150000001875 compounds Chemical class 0.000 claims description 103
• 235000019136 lipoic acid Nutrition 0.000 claims description 85
• 229960002663 thioctic acid Drugs 0.000 claims description 85
• 239000000203 mixture Substances 0.000 claims description 80
• 238000011282 treatment Methods 0.000 claims description 71
• 230000000694 effects Effects 0.000 claims description 65
• 230000014509 gene expression Effects 0.000 claims description 49
• 230000000598 lipoate effect Effects 0.000 claims description 49
• 239000003814 drug Substances 0.000 claims description 40
• 239000005541 ACE inhibitor Substances 0.000 claims description 38
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 38
• 238000000034 method Methods 0.000 claims description 33
• 108010001831 LDL receptors Proteins 0.000 claims description 30
• 241000282414 Homo sapiens Species 0.000 claims description 29
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 28
• 239000000556 agonist Substances 0.000 claims description 25
• DECGMUJJYLXRPA-UHFFFAOYSA-N (6-nitro-1,3-benzodioxol-5-yl) acetate Chemical compound C1=C([N+]([O-])=O)C(OC(=O)C)=CC2=C1OCO2 DECGMUJJYLXRPA-UHFFFAOYSA-N 0.000 claims description 24
• 208000024172 Cardiovascular disease Diseases 0.000 claims description 24
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 21
• 125000000217 alkyl group Chemical group 0.000 claims description 19
• 150000002632 lipids Chemical class 0.000 claims description 19
• 230000001225 therapeutic effect Effects 0.000 claims description 19
• BYOPSCVORPQJID-UHFFFAOYSA-N 6-nitro-1,3-benzodioxol-5-ol Chemical compound C1=C([N+]([O-])=O)C(O)=CC2=C1OCO2 BYOPSCVORPQJID-UHFFFAOYSA-N 0.000 claims description 18
• 206010020772 Hypertension Diseases 0.000 claims description 17
• 230000001965 increasing effect Effects 0.000 claims description 17
• IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 claims description 16
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 16
• 150000001412 amines Chemical class 0.000 claims description 16
• 108010007622 LDL Lipoproteins Proteins 0.000 claims description 15
• 102000007330 LDL Lipoproteins Human genes 0.000 claims description 15
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 15
• 239000003112 inhibitor Substances 0.000 claims description 15
• 239000002904 solvent Substances 0.000 claims description 15
• 206010012601 diabetes mellitus Diseases 0.000 claims description 14
• 230000002526 effect on cardiovascular system Effects 0.000 claims description 14
• 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 14
• 230000027455 binding Effects 0.000 claims description 13
• 230000000747 cardiac effect Effects 0.000 claims description 13
• 230000008602 contraction Effects 0.000 claims description 13
• 230000003247 decreasing effect Effects 0.000 claims description 13
• 208000027866 inflammatory disease Diseases 0.000 claims description 13
• 238000004519 manufacturing process Methods 0.000 claims description 13
• PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 12
• OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims description 12
• 239000008194 pharmaceutical composition Substances 0.000 claims description 12
• 102000005862 Angiotensin II Human genes 0.000 claims description 11
• 101800000733 Angiotensin-2 Proteins 0.000 claims description 11
• 208000032928 Dyslipidaemia Diseases 0.000 claims description 11
• 208000017170 Lipid metabolism disease Diseases 0.000 claims description 11
• LUSZGTFNYDARNI-UHFFFAOYSA-N Sesamol Chemical compound OC1=CC=C2OCOC2=C1 LUSZGTFNYDARNI-UHFFFAOYSA-N 0.000 claims description 11
• 229950006323 angiotensin ii Drugs 0.000 claims description 11
• 239000003937 drug carrier Substances 0.000 claims description 11
• 230000002757 inflammatory effect Effects 0.000 claims description 11
• 230000002792 vascular Effects 0.000 claims description 11
• 208000019553 vascular disease Diseases 0.000 claims description 11
• 229940123464 Thiazolidinedione Drugs 0.000 claims description 10
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 10
• IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 claims description 10
• 229960004373 acetylcholine Drugs 0.000 claims description 10
• 150000001408 amides Chemical group 0.000 claims description 10
• 229940049953 phenylacetate Drugs 0.000 claims description 10
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 9
• 125000000524 functional group Chemical group 0.000 claims description 9
• 208000017169 kidney disease Diseases 0.000 claims description 9
• 125000003977 lipoyl group Chemical group S1SC(C([H])([H])C(C(C(C(=O)[*])([H])[H])([H])[H])([H])[H])([H])C([H])([H])C1([H])[H] 0.000 claims description 9
• 238000003756 stirring Methods 0.000 claims description 9
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 9
• 125000001560 (R)-dihydrolipoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[C@](S[H])([H])C([H])([H])C([H])([H])S[H] 0.000 claims description 8
• ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims description 8
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 8
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 8
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 8
• 125000004494 ethyl ester group Chemical group 0.000 claims description 8
• AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims description 8
• 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 8
• 208000024891 symptom Diseases 0.000 claims description 8
• 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims description 7
• 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims description 7
• 150000008431 aliphatic amides Chemical class 0.000 claims description 7
• 150000008430 aromatic amides Chemical class 0.000 claims description 7
• 239000003795 chemical substances by application Substances 0.000 claims description 7
• 230000001419 dependent effect Effects 0.000 claims description 7
• 230000008021 deposition Effects 0.000 claims description 7
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
• 208000023516 stroke disease Diseases 0.000 claims description 7
• QNJMUNKUQDDPCI-UHFFFAOYSA-N 1,3-benzodioxol-5-yl acetate Chemical compound CC(=O)OC1=CC=C2OCOC2=C1 QNJMUNKUQDDPCI-UHFFFAOYSA-N 0.000 claims description 6
• 229940125364 angiotensin receptor blocker Drugs 0.000 claims description 6
• 230000003110 anti-inflammatory effect Effects 0.000 claims description 6
• 239000002876 beta blocker Substances 0.000 claims description 6
• 229940097320 beta blocking agent Drugs 0.000 claims description 6
• 239000001257 hydrogen Substances 0.000 claims description 6
• 229910052739 hydrogen Inorganic materials 0.000 claims description 6
• 230000007505 plaque formation Effects 0.000 claims description 6
• BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims description 5
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
• 230000035602 clotting Effects 0.000 claims description 5
• 229940125753 fibrate Drugs 0.000 claims description 5
• 210000002540 macrophage Anatomy 0.000 claims description 5
• 238000002360 preparation method Methods 0.000 claims description 5
• KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims description 4
• WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 4
• WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims description 4
• 206010022489 Insulin Resistance Diseases 0.000 claims description 4
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 4
• 101150014691 PPARA gene Proteins 0.000 claims description 4
• QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 claims description 4
• 150000001448 anilines Chemical class 0.000 claims description 4
• 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 4
• 239000003153 chemical reaction reagent Substances 0.000 claims description 4
• 235000013985 cinnamic acid Nutrition 0.000 claims description 4
• 229930016911 cinnamic acid Natural products 0.000 claims description 4
• 150000002148 esters Chemical class 0.000 claims description 4
• 150000002170 ethers Chemical class 0.000 claims description 4
• KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims description 4
• 235000001785 ferulic acid Nutrition 0.000 claims description 4
• 229940114124 ferulic acid Drugs 0.000 claims description 4
• KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims description 4
• 229910052736 halogen Chemical class 0.000 claims description 4
• 150000002367 halogens Chemical class 0.000 claims description 4
• 125000000623 heterocyclic group Chemical group 0.000 claims description 4
• 230000002401 inhibitory effect Effects 0.000 claims description 4
• 150000002537 isoquinolines Chemical class 0.000 claims description 4
• HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Chemical class OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 claims description 4
• 150000004702 methyl esters Chemical class 0.000 claims description 4
• WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims description 4
• 229960003512 nicotinic acid Drugs 0.000 claims description 4
• 235000001968 nicotinic acid Nutrition 0.000 claims description 4
• 239000011664 nicotinic acid Substances 0.000 claims description 4
• HXEACLLIILLPRG-UHFFFAOYSA-N pipecolic acid Chemical class OC(=O)C1CCCCN1 HXEACLLIILLPRG-UHFFFAOYSA-N 0.000 claims description 4
• 150000003147 proline derivatives Chemical class 0.000 claims description 4
• 102000005962 receptors Human genes 0.000 claims description 4
• 108020003175 receptors Proteins 0.000 claims description 4
• DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 claims description 4
• QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims description 4
• UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 4
• 108010016731 PPAR gamma Proteins 0.000 claims description 3
• 230000008595 infiltration Effects 0.000 claims description 3
• 238000001764 infiltration Methods 0.000 claims description 3
• 238000002156 mixing Methods 0.000 claims description 3
• 210000002460 smooth muscle Anatomy 0.000 claims description 3
• 235000015872 dietary supplement Nutrition 0.000 claims description 2
• 239000003446 ligand Substances 0.000 claims description 2
• PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 claims description 2
• 239000012299 nitrogen atmosphere Substances 0.000 claims description 2
• 230000024883 vasodilation Effects 0.000 claims description 2
• 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 8
• HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 6
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 3
• 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 claims 3
• 229940125881 cholesteryl ester transfer protein inhibitor Drugs 0.000 claims 3
• 150000002431 hydrogen Chemical class 0.000 claims 3
• 125000002883 imidazolyl group Chemical group 0.000 claims 3
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
• 102000000853 LDL receptors Human genes 0.000 claims 2
• 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 claims 2
• 230000008878 coupling Effects 0.000 claims 2
• 238000010168 coupling process Methods 0.000 claims 2
• 238000005859 coupling reaction Methods 0.000 claims 2
• 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims 2
• CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 claims 1
• 102000000536 PPAR gamma Human genes 0.000 claims 1
• ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical compound O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims 1
• 241001465754 Metazoa Species 0.000 description 72
• 241000283973 Oryctolagus cuniculus Species 0.000 description 70
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 64
• 201000001320 Atherosclerosis Diseases 0.000 description 42
• 238000002474 experimental method Methods 0.000 description 42
• 210000004027 cell Anatomy 0.000 description 38
• 229940079593 drug Drugs 0.000 description 32
• SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 29
• 229960001802 phenylephrine Drugs 0.000 description 29
• 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 28
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 28
• 238000002595 magnetic resonance imaging Methods 0.000 description 28
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
• 235000012000 cholesterol Nutrition 0.000 description 27
• 230000004044 response Effects 0.000 description 25
• 238000002560 therapeutic procedure Methods 0.000 description 24
• 235000009200 high fat diet Nutrition 0.000 description 23
• 208000010125 myocardial infarction Diseases 0.000 description 23
• 108090000623 proteins and genes Proteins 0.000 description 22
• WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 20
• 230000015572 biosynthetic process Effects 0.000 description 20
• 208000000059 Dyspnea Diseases 0.000 description 19
• 206010013975 Dyspnoeas Diseases 0.000 description 19
• 230000004913 activation Effects 0.000 description 19
• 208000013220 shortness of breath Diseases 0.000 description 19
• 206010008479 Chest Pain Diseases 0.000 description 18
• 238000005259 measurement Methods 0.000 description 17
• 230000002829 reductive effect Effects 0.000 description 17
• 210000000702 aorta abdominal Anatomy 0.000 description 16
• 210000004351 coronary vessel Anatomy 0.000 description 16
• 238000001543 one-way ANOVA Methods 0.000 description 16
• 230000009467 reduction Effects 0.000 description 16
• 238000003786 synthesis reaction Methods 0.000 description 16
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 15
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 15
• 102100040247 Tumor necrosis factor Human genes 0.000 description 15
• 229960002897 heparin Drugs 0.000 description 15
• 229920000669 heparin Polymers 0.000 description 15
• 239000003981 vehicle Substances 0.000 description 15
• 102000004877 Insulin Human genes 0.000 description 14
• 108090001061 Insulin Proteins 0.000 description 14
• 229960001138 acetylsalicylic acid Drugs 0.000 description 14
• 229940125396 insulin Drugs 0.000 description 14
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 13
• 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 13
• 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 13
• 238000003556 assay Methods 0.000 description 13
• GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 13
• XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 13
• 230000006872 improvement Effects 0.000 description 13
• 229940083618 sodium nitroprusside Drugs 0.000 description 13
• 238000002583 angiography Methods 0.000 description 12
• 210000002376 aorta thoracic Anatomy 0.000 description 12
• 238000001727 in vivo Methods 0.000 description 12
• 102000004169 proteins and genes Human genes 0.000 description 12
• 238000001262 western blot Methods 0.000 description 12
• 238000002965 ELISA Methods 0.000 description 11
• 210000000709 aorta Anatomy 0.000 description 11
• 238000009534 blood test Methods 0.000 description 11
• 229960003958 clopidogrel bisulfate Drugs 0.000 description 11
• 230000007423 decrease Effects 0.000 description 11
• 210000004185 liver Anatomy 0.000 description 11
• 108020004999 messenger RNA Proteins 0.000 description 11
• 238000011587 new zealand white rabbit Methods 0.000 description 11
• 210000001519 tissue Anatomy 0.000 description 11
• CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 10
• 238000008214 LDL Cholesterol Methods 0.000 description 10
• 210000004369 blood Anatomy 0.000 description 10
• 239000008280 blood Substances 0.000 description 10
• 238000006243 chemical reaction Methods 0.000 description 10
• 238000009472 formulation Methods 0.000 description 10
• 239000001103 potassium chloride Substances 0.000 description 10
• 235000011164 potassium chloride Nutrition 0.000 description 10
• 239000000047 product Substances 0.000 description 10
• 239000000243 solution Substances 0.000 description 10
• 150000003626 triacylglycerols Chemical class 0.000 description 10
• PXGPLTODNUVGFL-NAPLMKITSA-N 8-epi-prostaglandin F2alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-NAPLMKITSA-N 0.000 description 9
• ZSLZBFCDCINBPY-ZSJPKINUSA-N Acetyl-CoA Natural products O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 9
• 206010033557 Palpitations Diseases 0.000 description 9
• 208000006011 Stroke Diseases 0.000 description 9
• OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 9
• 230000036542 oxidative stress Effects 0.000 description 9
• 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 8
• 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 8
• 108010062497 VLDL Lipoproteins Proteins 0.000 description 8
• 239000012190 activator Substances 0.000 description 8
• 230000001154 acute effect Effects 0.000 description 8
• 238000000540 analysis of variance Methods 0.000 description 8
• 210000001367 artery Anatomy 0.000 description 8
• FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 8
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
• 210000004165 myocardium Anatomy 0.000 description 8
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
• 239000002953 phosphate buffered saline Substances 0.000 description 8
• 230000001105 regulatory effect Effects 0.000 description 8
• 238000010186 staining Methods 0.000 description 8
• 239000000126 substance Substances 0.000 description 8
• 238000001356 surgical procedure Methods 0.000 description 8
• XYJODUBPWNZLML-UHFFFAOYSA-N 5-ethyl-6-phenyl-6h-phenanthridine-3,8-diamine Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2N(CC)C1C1=CC=CC=C1 XYJODUBPWNZLML-UHFFFAOYSA-N 0.000 description 7
• 206010061218 Inflammation Diseases 0.000 description 7
• 108010007859 Lisinopril Proteins 0.000 description 7
• 108010057466 NF-kappa B Proteins 0.000 description 7
• 102000003945 NF-kappa B Human genes 0.000 description 7
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
• 230000000692 anti-sense effect Effects 0.000 description 7
• 230000003143 atherosclerotic effect Effects 0.000 description 7
• 230000008901 benefit Effects 0.000 description 7
• 229960000830 captopril Drugs 0.000 description 7
• 208000035475 disorder Diseases 0.000 description 7
• 231100000673 dose–response relationship Toxicity 0.000 description 7
• 238000002651 drug therapy Methods 0.000 description 7
• 210000003038 endothelium Anatomy 0.000 description 7
• 230000004054 inflammatory process Effects 0.000 description 7
• RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 7
• HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 7
• 238000003753 real-time PCR Methods 0.000 description 7
• 210000000115 thoracic cavity Anatomy 0.000 description 7
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
• 208000037260 Atherosclerotic Plaque Diseases 0.000 description 6
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
• 208000013600 Diabetic vascular disease Diseases 0.000 description 6
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 6
• 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 6
• 239000005089 Luciferase Substances 0.000 description 6
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
• 208000029549 Muscle injury Diseases 0.000 description 6
• 206010028813 Nausea Diseases 0.000 description 6
• 208000002193 Pain Diseases 0.000 description 6
• 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 description 6
• 101710180553 Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 6
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
• 208000006117 ST-elevation myocardial infarction Diseases 0.000 description 6
• 108700012920 TNF Proteins 0.000 description 6
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 6
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 6
• 206010047700 Vomiting Diseases 0.000 description 6
• XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 6
• 230000003187 abdominal effect Effects 0.000 description 6
• 229910052799 carbon Inorganic materials 0.000 description 6
• 238000011976 chest X-ray Methods 0.000 description 6
• 238000012937 correction Methods 0.000 description 6
• 238000002425 crystallisation Methods 0.000 description 6
• 230000001086 cytosolic effect Effects 0.000 description 6
• 230000002354 daily effect Effects 0.000 description 6
• 201000009101 diabetic angiopathy Diseases 0.000 description 6
• 210000002889 endothelial cell Anatomy 0.000 description 6
• OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 6
• 238000002347 injection Methods 0.000 description 6
• 239000007924 injection Substances 0.000 description 6
• 210000003734 kidney Anatomy 0.000 description 6
• 230000008693 nausea Effects 0.000 description 6
• 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 6
• 230000003647 oxidation Effects 0.000 description 6
• 238000007254 oxidation reaction Methods 0.000 description 6
• 230000036407 pain Effects 0.000 description 6
• 230000002093 peripheral effect Effects 0.000 description 6
• 230000000770 proinflammatory effect Effects 0.000 description 6
• 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 6
• 229960003401 ramipril Drugs 0.000 description 6
• BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 6
• 239000007787 solid Substances 0.000 description 6
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
• 230000035900 sweating Effects 0.000 description 6
• 229960000187 tissue plasminogen activator Drugs 0.000 description 6
• 230000008673 vomiting Effects 0.000 description 6
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
• 241000282412 Homo Species 0.000 description 5
• 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 5
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
• VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 5
• 102000040945 Transcription factor Human genes 0.000 description 5
• 108091023040 Transcription factor Proteins 0.000 description 5
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 5
• 238000004458 analytical method Methods 0.000 description 5
• 229940030600 antihypertensive agent Drugs 0.000 description 5
• 239000002220 antihypertensive agent Substances 0.000 description 5
• 230000036772 blood pressure Effects 0.000 description 5
• 230000007211 cardiovascular event Effects 0.000 description 5
• 238000004113 cell culture Methods 0.000 description 5
• 210000000038 chest Anatomy 0.000 description 5
• 238000001514 detection method Methods 0.000 description 5
• 235000005911 diet Nutrition 0.000 description 5
• 230000037213 diet Effects 0.000 description 5
• 229940088598 enzyme Drugs 0.000 description 5
• 229940093499 ethyl acetate Drugs 0.000 description 5
• 235000019439 ethyl acetate Nutrition 0.000 description 5
• 229960000815 ezetimibe Drugs 0.000 description 5
• 230000006870 function Effects 0.000 description 5
• 239000001963 growth medium Substances 0.000 description 5
• 238000000338 in vitro Methods 0.000 description 5
• 230000005764 inhibitory process Effects 0.000 description 5
• 230000000977 initiatory effect Effects 0.000 description 5
• 229960002394 lisinopril Drugs 0.000 description 5
• 239000012528 membrane Substances 0.000 description 5
• 230000005012 migration Effects 0.000 description 5
• 238000013508 migration Methods 0.000 description 5
• 238000007491 morphometric analysis Methods 0.000 description 5
• 230000005945 translocation Effects 0.000 description 5
• 210000003606 umbilical vein Anatomy 0.000 description 5
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
• BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 4
• XRSKRSVTUVLURN-UHFFFAOYSA-N 1,3-benzodioxol-4-ol Chemical compound OC1=CC=CC2=C1OCO2 XRSKRSVTUVLURN-UHFFFAOYSA-N 0.000 description 4
• BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 4
• FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 4
• XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 4
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
• 206010007559 Cardiac failure congestive Diseases 0.000 description 4
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
• 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 description 4
• 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 description 4
• 102000004127 Cytokines Human genes 0.000 description 4
• 108090000695 Cytokines Proteins 0.000 description 4
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 4
• 208000032131 Diabetic Neuropathies Diseases 0.000 description 4
• 102000004190 Enzymes Human genes 0.000 description 4
• 108090000790 Enzymes Proteins 0.000 description 4
• 108010010803 Gelatin Proteins 0.000 description 4
• 108010010234 HDL Lipoproteins Proteins 0.000 description 4
• 206010019280 Heart failures Diseases 0.000 description 4
• LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 4
• YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 4
• 229930182558 Sterol Natural products 0.000 description 4
• 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 4
• 108010069201 VLDL Cholesterol Proteins 0.000 description 4
• 230000035508 accumulation Effects 0.000 description 4
• 238000009825 accumulation Methods 0.000 description 4
• 238000010306 acid treatment Methods 0.000 description 4
• 230000009471 action Effects 0.000 description 4
• 239000003524 antilipemic agent Substances 0.000 description 4
• 206010003246 arthritis Diseases 0.000 description 4
• 230000033228 biological regulation Effects 0.000 description 4
• 239000002775 capsule Substances 0.000 description 4
• 230000008025 crystallization Effects 0.000 description 4
• 210000000805 cytoplasm Anatomy 0.000 description 4
• 208000033679 diabetic kidney disease Diseases 0.000 description 4
• 238000010586 diagram Methods 0.000 description 4
• BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 4
• 239000008273 gelatin Substances 0.000 description 4
• 229920000159 gelatin Polymers 0.000 description 4
• 235000019322 gelatine Nutrition 0.000 description 4
• 235000011852 gelatine desserts Nutrition 0.000 description 4
• 210000002216 heart Anatomy 0.000 description 4
• 208000019622 heart disease Diseases 0.000 description 4
• 238000001802 infusion Methods 0.000 description 4
• 239000006166 lysate Substances 0.000 description 4
• VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 4
• 230000005937 nuclear translocation Effects 0.000 description 4
• WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
• 239000002243 precursor Substances 0.000 description 4
• 238000002203 pretreatment Methods 0.000 description 4
• 230000002265 prevention Effects 0.000 description 4
• 230000035755 proliferation Effects 0.000 description 4
• 229940076788 pyruvate Drugs 0.000 description 4
• 230000009863 secondary prevention Effects 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• 239000007858 starting material Substances 0.000 description 4
• 150000003432 sterols Chemical class 0.000 description 4
• 235000003702 sterols Nutrition 0.000 description 4
• 230000000638 stimulation Effects 0.000 description 4
• 238000012360 testing method Methods 0.000 description 4
• VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
• 229960002051 trandolapril Drugs 0.000 description 4
• 238000011870 unpaired t-test Methods 0.000 description 4
• 229940124549 vasodilator Drugs 0.000 description 4
• 239000003071 vasodilator agent Substances 0.000 description 4
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
• WBDUYARIFXBFOC-UHFFFAOYSA-N 2-nitro-1,3-benzodioxol-4-ol Chemical compound OC1=CC=CC2=C1OC([N+]([O-])=O)O2 WBDUYARIFXBFOC-UHFFFAOYSA-N 0.000 description 3
• KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 description 3
• 108010074051 C-Reactive Protein Proteins 0.000 description 3
• 102100032752 C-reactive protein Human genes 0.000 description 3
• 108010061435 Enalapril Proteins 0.000 description 3
• 102400000686 Endothelin-1 Human genes 0.000 description 3
• 101800004490 Endothelin-1 Proteins 0.000 description 3
• 229910052688 Gadolinium Inorganic materials 0.000 description 3
• HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 239000007995 HEPES buffer Substances 0.000 description 3
• 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 3
• 108060001084 Luciferase Proteins 0.000 description 3
• 102100025136 Macrosialin Human genes 0.000 description 3
• UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 description 3
• 241000699670 Mus sp. Species 0.000 description 3
• 102000007999 Nuclear Proteins Human genes 0.000 description 3
• 108010089610 Nuclear Proteins Proteins 0.000 description 3
• 102000004316 Oxidoreductases Human genes 0.000 description 3
• 108090000854 Oxidoreductases Proteins 0.000 description 3
• 229930040373 Paraformaldehyde Natural products 0.000 description 3
• 229930182555 Penicillin Natural products 0.000 description 3
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
• 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 3
• 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 3
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 3
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 3
• 238000011529 RT qPCR Methods 0.000 description 3
• 108010063499 Sigma Factor Proteins 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 108010023197 Streptokinase Proteins 0.000 description 3
• 238000000692 Student's t-test Methods 0.000 description 3
• 102000004142 Trypsin Human genes 0.000 description 3
• 108090000631 Trypsin Proteins 0.000 description 3
• 229960000583 acetic acid Drugs 0.000 description 3
• 238000010171 animal model Methods 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• 229960004530 benazepril Drugs 0.000 description 3
• 230000004071 biological effect Effects 0.000 description 3
• 230000037396 body weight Effects 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 229910002092 carbon dioxide Inorganic materials 0.000 description 3
• 239000000969 carrier Substances 0.000 description 3
• 230000015556 catabolic process Effects 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• 230000005754 cellular signaling Effects 0.000 description 3
• 208000026106 cerebrovascular disease Diseases 0.000 description 3
• 238000012512 characterization method Methods 0.000 description 3
• 208000029078 coronary artery disease Diseases 0.000 description 3
• GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 3
• 229960000873 enalapril Drugs 0.000 description 3
• 238000011156 evaluation Methods 0.000 description 3
• YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 3
• 229960002297 fenofibrate Drugs 0.000 description 3
• 239000012894 fetal calf serum Substances 0.000 description 3
• 239000003527 fibrinolytic agent Substances 0.000 description 3
• 229960002490 fosinopril Drugs 0.000 description 3
• UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 3
• 229960003627 gemfibrozil Drugs 0.000 description 3
• 239000012362 glacial acetic acid Substances 0.000 description 3
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
• 239000003102 growth factor Substances 0.000 description 3
• 230000036541 health Effects 0.000 description 3
• 238000003384 imaging method Methods 0.000 description 3
• 238000003364 immunohistochemistry Methods 0.000 description 3
• 230000001939 inductive effect Effects 0.000 description 3
• 238000010255 intramuscular injection Methods 0.000 description 3
• 239000007927 intramuscular injection Substances 0.000 description 3
• 238000002608 intravascular ultrasound Methods 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 239000002502 liposome Substances 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 3
• KNJDBYZZKAZQNG-UHFFFAOYSA-N lucigenin Chemical compound [O-][N+]([O-])=O.[O-][N+]([O-])=O.C12=CC=CC=C2[N+](C)=C(C=CC=C2)C2=C1C1=C(C=CC=C2)C2=[N+](C)C2=CC=CC=C12 KNJDBYZZKAZQNG-UHFFFAOYSA-N 0.000 description 3
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
• 235000019341 magnesium sulphate Nutrition 0.000 description 3
• 230000002438 mitochondrial effect Effects 0.000 description 3
• 238000010899 nucleation Methods 0.000 description 3
• 210000000056 organ Anatomy 0.000 description 3
• 229910052760 oxygen Inorganic materials 0.000 description 3
• 229920002866 paraformaldehyde Polymers 0.000 description 3
• 229940049954 penicillin Drugs 0.000 description 3
• IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 3
• 229960002582 perindopril Drugs 0.000 description 3
• 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 3
• 239000013612 plasmid Substances 0.000 description 3
• 230000001124 posttranscriptional effect Effects 0.000 description 3
• VWBQYTRBTXKKOG-IYNICTALSA-M pravastatin sodium Chemical compound [Na+].C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 VWBQYTRBTXKKOG-IYNICTALSA-M 0.000 description 3
• JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 3
• 229960001455 quinapril Drugs 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 230000002207 retinal effect Effects 0.000 description 3
• 206010039073 rheumatoid arthritis Diseases 0.000 description 3
• RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 3
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
• 229960005202 streptokinase Drugs 0.000 description 3
• 229960005322 streptomycin Drugs 0.000 description 3
• 125000001424 substituent group Chemical group 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• 238000012353 t test Methods 0.000 description 3
• 238000004809 thin layer chromatography Methods 0.000 description 3
• 238000002723 toxicity assay Methods 0.000 description 3
• 239000012588 trypsin Substances 0.000 description 3
• 239000005526 vasoconstrictor agent Substances 0.000 description 3
• 210000003462 vein Anatomy 0.000 description 3
• ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 2
• UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
• AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
• 206010002383 Angina Pectoris Diseases 0.000 description 2
• 206010002388 Angina unstable Diseases 0.000 description 2
• 101800000734 Angiotensin-1 Proteins 0.000 description 2
• 102400000344 Angiotensin-1 Human genes 0.000 description 2
• 108010071619 Apolipoproteins Proteins 0.000 description 2
• 102000007592 Apolipoproteins Human genes 0.000 description 2
• 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 2
• 208000006820 Arthralgia Diseases 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 2
• 238000011740 C57BL/6 mouse Methods 0.000 description 2
• 229940127291 Calcium channel antagonist Drugs 0.000 description 2
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
• 206010053567 Coagulopathies Diseases 0.000 description 2
• 102000008186 Collagen Human genes 0.000 description 2
• 108010035532 Collagen Proteins 0.000 description 2
• 208000031288 Combined hyperlipidaemia Diseases 0.000 description 2
• 206010070901 Diabetic dyslipidaemia Diseases 0.000 description 2
• 108010066671 Enalaprilat Proteins 0.000 description 2
• 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
• 208000030673 Homozygous familial hypercholesterolemia Diseases 0.000 description 2
• 208000035150 Hypercholesterolemia Diseases 0.000 description 2
• 208000031226 Hyperlipidaemia Diseases 0.000 description 2
• 208000001953 Hypotension Diseases 0.000 description 2
• 108010002352 Interleukin-1 Proteins 0.000 description 2
• 102000000589 Interleukin-1 Human genes 0.000 description 2
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
• 108010092694 L-Selectin Proteins 0.000 description 2
• 102000004856 Lectins Human genes 0.000 description 2
• 102000004895 Lipoproteins Human genes 0.000 description 2
• 108090001030 Lipoproteins Proteins 0.000 description 2
• PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
• 208000000770 Non-ST Elevated Myocardial Infarction Diseases 0.000 description 2
• 108010035766 P-Selectin Proteins 0.000 description 2
• 102100023472 P-selectin Human genes 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 208000005764 Peripheral Arterial Disease Diseases 0.000 description 2
• 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 2
• 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 2
• LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
• UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
• 102000009822 Sterol Regulatory Element Binding Proteins Human genes 0.000 description 2
• 108010020396 Sterol Regulatory Element Binding Proteins Proteins 0.000 description 2
• 229940100389 Sulfonylurea Drugs 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 102000013394 Troponin I Human genes 0.000 description 2
• 108010065729 Troponin I Proteins 0.000 description 2
• 208000007814 Unstable Angina Diseases 0.000 description 2
• 229940062352 aceon Drugs 0.000 description 2
• 230000021736 acetylation Effects 0.000 description 2
• 238000006640 acetylation reaction Methods 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 230000032683 aging Effects 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 2
• 239000002333 angiotensin II receptor antagonist Substances 0.000 description 2
• 230000000879 anti-atherosclerotic effect Effects 0.000 description 2
• 239000003963 antioxidant agent Substances 0.000 description 2
• 230000003078 antioxidant effect Effects 0.000 description 2
• 235000006708 antioxidants Nutrition 0.000 description 2
• DFYRUELUNQRZTB-UHFFFAOYSA-N apocynin Chemical compound COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 description 2
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
• FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 description 2
• 229960000516 bezafibrate Drugs 0.000 description 2
• IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 2
• 230000004531 blood pressure lowering effect Effects 0.000 description 2
• 210000004204 blood vessel Anatomy 0.000 description 2
• 239000000480 calcium channel blocker Substances 0.000 description 2
• 239000001110 calcium chloride Substances 0.000 description 2
• 235000011148 calcium chloride Nutrition 0.000 description 2
• 239000007894 caplet Substances 0.000 description 2
• 239000001569 carbon dioxide Substances 0.000 description 2
• 210000001715 carotid artery Anatomy 0.000 description 2
• 230000003833 cell viability Effects 0.000 description 2
• 230000007541 cellular toxicity Effects 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 2
• 229960005025 cilazapril Drugs 0.000 description 2
• 229960003009 clopidogrel Drugs 0.000 description 2
• 229920001436 collagen Polymers 0.000 description 2
• 238000002648 combination therapy Methods 0.000 description 2
• 238000013270 controlled release Methods 0.000 description 2
• 230000001276 controlling effect Effects 0.000 description 2
• 208000026758 coronary atherosclerosis Diseases 0.000 description 2
• 239000007822 coupling agent Substances 0.000 description 2
• 239000012043 crude product Substances 0.000 description 2
• 238000012303 cytoplasmic staining Methods 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 238000006731 degradation reaction Methods 0.000 description 2
• 238000002716 delivery method Methods 0.000 description 2
• 201000002342 diabetic polyneuropathy Diseases 0.000 description 2
• 235000014113 dietary fatty acids Nutrition 0.000 description 2
• 230000008034 disappearance Effects 0.000 description 2
• 238000004090 dissolution Methods 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• 239000002934 diuretic Substances 0.000 description 2
• 229940030606 diuretics Drugs 0.000 description 2
• 210000000624 ear auricle Anatomy 0.000 description 2
• 230000008753 endothelial function Effects 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 230000029142 excretion Effects 0.000 description 2
• 238000013401 experimental design Methods 0.000 description 2
• 239000000284 extract Substances 0.000 description 2
• 239000000194 fatty acid Substances 0.000 description 2
• 229930195729 fatty acid Natural products 0.000 description 2
• 150000004665 fatty acids Chemical class 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
• 230000010005 growth-factor like effect Effects 0.000 description 2
• WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 2
• 239000007943 implant Substances 0.000 description 2
• 238000012606 in vitro cell culture Methods 0.000 description 2
• 238000011065 in-situ storage Methods 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 201000004332 intermediate coronary syndrome Diseases 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 230000001788 irregular Effects 0.000 description 2
• 229960003299 ketamine Drugs 0.000 description 2
• 231100000636 lethal dose Toxicity 0.000 description 2
• 238000011068 loading method Methods 0.000 description 2
• 208000012866 low blood pressure Diseases 0.000 description 2
• 210000003141 lower extremity Anatomy 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 208000030159 metabolic disease Diseases 0.000 description 2
• XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
• 229960003105 metformin Drugs 0.000 description 2
• 210000003470 mitochondria Anatomy 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 229960005170 moexipril Drugs 0.000 description 2
• 208000031225 myocardial ischemia Diseases 0.000 description 2
• 150000002823 nitrates Chemical class 0.000 description 2
• 229910017604 nitric acid Inorganic materials 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 239000001301 oxygen Substances 0.000 description 2
• 229960001412 pentobarbital Drugs 0.000 description 2
• 230000010412 perfusion Effects 0.000 description 2
• IYNMDWMQHSMDDE-MHXJNQAMSA-N perindopril erbumine Chemical compound CC(C)(C)N.C1CCC[C@@H]2N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H](C(O)=O)C[C@@H]21 IYNMDWMQHSMDDE-MHXJNQAMSA-N 0.000 description 2
• 210000002824 peroxisome Anatomy 0.000 description 2
• YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• 230000001766 physiological effect Effects 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
• 210000003137 popliteal artery Anatomy 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 238000012746 preparative thin layer chromatography Methods 0.000 description 2
• 230000009862 primary prevention Effects 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 230000001681 protective effect Effects 0.000 description 2
• 238000000746 purification Methods 0.000 description 2
• 238000011002 quantification Methods 0.000 description 2
• 150000003254 radicals Chemical class 0.000 description 2
• 230000035484 reaction time Effects 0.000 description 2
• 239000003642 reactive oxygen metabolite Substances 0.000 description 2
• 230000000284 resting effect Effects 0.000 description 2
• 230000000250 revascularization Effects 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 229960004586 rosiglitazone Drugs 0.000 description 2
• 239000012266 salt solution Substances 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 238000007619 statistical method Methods 0.000 description 2
• YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
• 230000002459 sustained effect Effects 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• RYCLIXPGLDDLTM-UHFFFAOYSA-J tetrapotassium;phosphonato phosphate Chemical compound [K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O RYCLIXPGLDDLTM-UHFFFAOYSA-J 0.000 description 2
• 125000003831 tetrazolyl group Chemical group 0.000 description 2
• 125000003396 thiol group Chemical group [H]S* 0.000 description 2
• 230000036962 time dependent Effects 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• 238000002604 ultrasonography Methods 0.000 description 2
• 230000002485 urinary effect Effects 0.000 description 2
• 230000004865 vascular response Effects 0.000 description 2
• BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
• 229960001600 xylazine Drugs 0.000 description 2
• OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 description 1
• AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
• VJOQERFEYIOHCO-UHFFFAOYSA-N 1-(1,2,4-benzotrioxin-3-yl)ethanone Chemical compound C1=CC=C2OC(C(=O)C)OOC2=C1 VJOQERFEYIOHCO-UHFFFAOYSA-N 0.000 description 1
• 101150028074 2 gene Proteins 0.000 description 1
• VJDVWBDSMDTODO-UHFFFAOYSA-N 2-methoxyethyl 4-amino-4-oxobutanoate Chemical compound COCCOC(=O)CCC(N)=O VJDVWBDSMDTODO-UHFFFAOYSA-N 0.000 description 1
• NRGITDCYCLOXKL-UHFFFAOYSA-N 2-nitro-1,3-benzodioxol-4-ol;6-nitro-1,3-benzodioxol-5-ol Chemical compound OC1=CC=CC2=C1OC([N+]([O-])=O)O2.C1=C([N+]([O-])=O)C(O)=CC2=C1OCO2 NRGITDCYCLOXKL-UHFFFAOYSA-N 0.000 description 1
• 108010046716 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) Proteins 0.000 description 1
• XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• NQDZURVPVBKEPB-UHFFFAOYSA-N 8-(3H-dithiol-3-yl)octanoic acid Chemical compound OC(=O)CCCCCCCC1SSC=C1 NQDZURVPVBKEPB-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• 230000002407 ATP formation Effects 0.000 description 1
• 102000007469 Actins Human genes 0.000 description 1
• 108010085238 Actins Proteins 0.000 description 1
• 208000003130 Alcoholic Neuropathy Diseases 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 108020004306 Alpha-ketoglutarate dehydrogenase Proteins 0.000 description 1
• 102000006589 Alpha-ketoglutarate dehydrogenase Human genes 0.000 description 1
• 206010002091 Anaesthesia Diseases 0.000 description 1
• XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
• XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
• 238000000035 BCA protein assay Methods 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 230000004568 DNA-binding Effects 0.000 description 1
• 101710088194 Dehydrogenase Proteins 0.000 description 1
• 108020005199 Dehydrogenases Proteins 0.000 description 1
• 102000028526 Dihydrolipoamide Dehydrogenase Human genes 0.000 description 1
• 108010028127 Dihydrolipoamide Dehydrogenase Proteins 0.000 description 1
• MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
• 238000008787 Direct HDL Methods 0.000 description 1
• 206010013710 Drug interaction Diseases 0.000 description 1
• 108010024212 E-Selectin Proteins 0.000 description 1
• 102100023471 E-selectin Human genes 0.000 description 1
• 238000008157 ELISA kit Methods 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 102100039556 Galectin-4 Human genes 0.000 description 1
• 206010073069 Hepatic cancer Diseases 0.000 description 1
• 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
• 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
• 206010020608 Hypercoagulation Diseases 0.000 description 1
• 206010021143 Hypoxia Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 238000012404 In vitro experiment Methods 0.000 description 1
• 102100033467 L-selectin Human genes 0.000 description 1
• 102000016551 L-selectin Human genes 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 238000000134 MTT assay Methods 0.000 description 1
• 231100000002 MTT assay Toxicity 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 208000001145 Metabolic Syndrome Diseases 0.000 description 1
• 206010027525 Microalbuminuria Diseases 0.000 description 1
• 102000002568 Multienzyme Complexes Human genes 0.000 description 1
• 108010093369 Multienzyme Complexes Proteins 0.000 description 1
• 206010028980 Neoplasm Diseases 0.000 description 1
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 1
• 239000000020 Nitrocellulose Substances 0.000 description 1
• SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
• 239000000006 Nitroglycerin Substances 0.000 description 1
• 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
• 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
• 241000283977 Oryctolagus Species 0.000 description 1
• 208000018262 Peripheral vascular disease Diseases 0.000 description 1
• 108700020962 Peroxidase Proteins 0.000 description 1
• 102000003992 Peroxidases Human genes 0.000 description 1
• 206010036105 Polyneuropathy Diseases 0.000 description 1
• TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
• 238000010240 RT-PCR analysis Methods 0.000 description 1
• 208000001647 Renal Insufficiency Diseases 0.000 description 1
• RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
• AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 1
• CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• 208000007718 Stable Angina Diseases 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• 208000007536 Thrombosis Diseases 0.000 description 1
• 208000035868 Vascular inflammations Diseases 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 229940077422 accupril Drugs 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 238000001261 affinity purification Methods 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 150000001349 alkyl fluorides Chemical class 0.000 description 1
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
• 229940077927 altace Drugs 0.000 description 1
• 239000003708 ampul Substances 0.000 description 1
• MZZLGJHLQGUVPN-HAWMADMCSA-N anacetrapib Chemical compound COC1=CC(F)=C(C(C)C)C=C1C1=CC=C(C(F)(F)F)C=C1CN1C(=O)O[C@H](C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@@H]1C MZZLGJHLQGUVPN-HAWMADMCSA-N 0.000 description 1
• 229950000285 anacetrapib Drugs 0.000 description 1
• 230000037005 anaesthesia Effects 0.000 description 1
• 230000003466 anti-cipated effect Effects 0.000 description 1
• 230000003276 anti-hypertensive effect Effects 0.000 description 1
• 229940124599 anti-inflammatory drug Drugs 0.000 description 1
• 229930188866 apocynin Natural products 0.000 description 1
• 159000000032 aromatic acids Chemical class 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 229960005370 atorvastatin Drugs 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 239000003855 balanced salt solution Substances 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 230000000975 bioactive effect Effects 0.000 description 1
• 230000008499 blood brain barrier function Effects 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 210000001218 blood-brain barrier Anatomy 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• 150000005693 branched-chain amino acids Chemical class 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• 201000011510 cancer Diseases 0.000 description 1
• 229940097633 capoten Drugs 0.000 description 1
• 235000011089 carbon dioxide Nutrition 0.000 description 1
• 239000002327 cardiovascular agent Substances 0.000 description 1
• 229940125692 cardiovascular agent Drugs 0.000 description 1
• 210000000748 cardiovascular system Anatomy 0.000 description 1
• 238000006555 catalytic reaction Methods 0.000 description 1
• 238000000423 cell based assay Methods 0.000 description 1
• 239000013592 cell lysate Substances 0.000 description 1
• 150000005829 chemical entities Chemical class 0.000 description 1
• 239000000460 chlorine Substances 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• 230000004087 circulation Effects 0.000 description 1
• 229940000425 combination drug Drugs 0.000 description 1
• 229940066901 crestor Drugs 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 230000001186 cumulative effect Effects 0.000 description 1
• 238000005520 cutting process Methods 0.000 description 1
• 238000010217 densitometric analysis Methods 0.000 description 1
• KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
• 229960003964 deoxycholic acid Drugs 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 230000009699 differential effect Effects 0.000 description 1
• OZLBDYMWFAHSOQ-UHFFFAOYSA-N diphenyliodanium Chemical compound C=1C=CC=CC=1[I+]C1=CC=CC=C1 OZLBDYMWFAHSOQ-UHFFFAOYSA-N 0.000 description 1
• IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 238000001647 drug administration Methods 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 239000003596 drug target Substances 0.000 description 1
• 230000003086 effect on acetylcholine Effects 0.000 description 1
• 230000000225 effect on diabetes Effects 0.000 description 1
• 230000000667 effect on insulin Effects 0.000 description 1
• 238000001378 electrochemiluminescence detection Methods 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
• 229960002680 enalaprilat Drugs 0.000 description 1
• LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 description 1
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
• 210000003989 endothelium vascular Anatomy 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 210000003979 eosinophil Anatomy 0.000 description 1
• 238000011067 equilibration Methods 0.000 description 1
• 210000003743 erythrocyte Anatomy 0.000 description 1
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
• 229960005542 ethidium bromide Drugs 0.000 description 1
• 230000003203 everyday effect Effects 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 230000004136 fatty acid synthesis Effects 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 239000012467 final product Substances 0.000 description 1
• 238000003818 flash chromatography Methods 0.000 description 1
• 229910052731 fluorine Inorganic materials 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 229960003765 fluvastatin Drugs 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 235000012631 food intake Nutrition 0.000 description 1
• 239000012737 fresh medium Substances 0.000 description 1
• LGMLJQFQKXPRGA-VPVMAENOSA-K gadopentetate dimeglumine Chemical compound [Gd+3].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O LGMLJQFQKXPRGA-VPVMAENOSA-K 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 230000004153 glucose metabolism Effects 0.000 description 1
• 230000002641 glycemic effect Effects 0.000 description 1
• 229960003711 glyceryl trinitrate Drugs 0.000 description 1
• 210000002288 golgi apparatus Anatomy 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• 238000000265 homogenisation Methods 0.000 description 1
• 102000057041 human TNF Human genes 0.000 description 1
• 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
• 230000000260 hypercholesteremic effect Effects 0.000 description 1
• 230000007954 hypoxia Effects 0.000 description 1
• 238000002991 immunohistochemical analysis Methods 0.000 description 1
• 238000011532 immunohistochemical staining Methods 0.000 description 1
• 238000009169 immunotherapy Methods 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000008798 inflammatory stress Effects 0.000 description 1
• 238000009830 intercalation Methods 0.000 description 1
• 230000002687 intercalation Effects 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 201000006370 kidney failure Diseases 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 229940095570 lescol Drugs 0.000 description 1
• 230000037356 lipid metabolism Effects 0.000 description 1
• 229940002661 lipitor Drugs 0.000 description 1
• FCCDDURTIIUXBY-UHFFFAOYSA-N lipoamide Chemical compound NC(=O)CCCCC1CCSS1 FCCDDURTIIUXBY-UHFFFAOYSA-N 0.000 description 1
• 229940092923 livalo Drugs 0.000 description 1
• 201000002250 liver carcinoma Diseases 0.000 description 1
• 208000019423 liver disease Diseases 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 229940080268 lotensin Drugs 0.000 description 1
• 229960004844 lovastatin Drugs 0.000 description 1
• QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 229940103179 mavik Drugs 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 239000008155 medical solution Substances 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 238000006241 metabolic reaction Methods 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 229940099246 mevacor Drugs 0.000 description 1
• 229950009116 mevastatin Drugs 0.000 description 1
• AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 1
• BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 1
• 239000011859 microparticle Substances 0.000 description 1
• 239000004005 microsphere Substances 0.000 description 1
• 239000003068 molecular probe Substances 0.000 description 1
• 229940118178 monopril Drugs 0.000 description 1
• 230000003562 morphometric effect Effects 0.000 description 1
• 238000013425 morphometry Methods 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 239000002105 nanoparticle Substances 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 238000005895 oxidative decarboxylation reaction Methods 0.000 description 1
• 239000006179 pH buffering agent Substances 0.000 description 1
• 238000007427 paired t-test Methods 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000004031 partial agonist Substances 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 229940097156 peroxyl Drugs 0.000 description 1
• CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 229960005095 pioglitazone Drugs 0.000 description 1
• 229960002797 pitavastatin Drugs 0.000 description 1
• VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
• RHGYHLPFVJEAOC-FFNUKLMVSA-L pitavastatin calcium Chemical compound [Ca+2].[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1.[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 RHGYHLPFVJEAOC-FFNUKLMVSA-L 0.000 description 1
• 230000007406 plaque accumulation Effects 0.000 description 1
• 108010012938 polyethylene glycol-superoxide dismutase Proteins 0.000 description 1
• 230000007824 polyneuropathy Effects 0.000 description 1
• 230000012495 positive regulation of renal sodium excretion Effects 0.000 description 1
• 229940089484 pravachol Drugs 0.000 description 1
• 229960002965 pravastatin Drugs 0.000 description 1
• TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 229940088953 prinivil Drugs 0.000 description 1
• 230000007112 pro inflammatory response Effects 0.000 description 1
• 230000000861 pro-apoptotic effect Effects 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 229940107700 pyruvic acid Drugs 0.000 description 1
• IBBLRJGOOANPTQ-JKVLGAQCSA-N quinapril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 IBBLRJGOOANPTQ-JKVLGAQCSA-N 0.000 description 1
• 239000012132 radioimmunoprecipitation assay buffer Substances 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 239000000018 receptor agonist Substances 0.000 description 1
• 229940044601 receptor agonist Drugs 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 230000002040 relaxant effect Effects 0.000 description 1
• 210000002254 renal artery Anatomy 0.000 description 1
• 238000003571 reporter gene assay Methods 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 229960000672 rosuvastatin Drugs 0.000 description 1
• BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
• LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 description 1
• 239000000523 sample Substances 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 238000004062 sedimentation Methods 0.000 description 1
• 229920000260 silastic Polymers 0.000 description 1
• 229960002855 simvastatin Drugs 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• 230000000391 smoking effect Effects 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000001632 sodium acetate Substances 0.000 description 1
• 235000017281 sodium acetate Nutrition 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 238000005063 solubilization Methods 0.000 description 1
• 230000007928 solubilization Effects 0.000 description 1
• 239000011537 solubilization buffer Substances 0.000 description 1
• 229940061368 sonata Drugs 0.000 description 1
• 229940035044 sorbitan monolaurate Drugs 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 238000000528 statistical test Methods 0.000 description 1
• 230000003637 steroidlike Effects 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 230000009469 supplementation Effects 0.000 description 1
• 230000008093 supporting effect Effects 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 230000001839 systemic circulation Effects 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 150000001467 thiazolidinediones Chemical class 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 201000005665 thrombophilia Diseases 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 229940054495 univasc Drugs 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 230000004218 vascular function Effects 0.000 description 1
• 210000005166 vasculature Anatomy 0.000 description 1
• 229940099270 vasotec Drugs 0.000 description 1
• 229940088594 vitamin Drugs 0.000 description 1
• 239000011782 vitamin Substances 0.000 description 1
• 235000013343 vitamin Nutrition 0.000 description 1
• 229930003231 vitamin Natural products 0.000 description 1
• 150000003722 vitamin derivatives Chemical class 0.000 description 1
• PNAMDJVUJCJOIX-XVZWKFLSSA-N vytorin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1.N1([C@@H]([C@H](C1=O)CC[C@@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 PNAMDJVUJCJOIX-XVZWKFLSSA-N 0.000 description 1
• 229940009349 vytorin Drugs 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1
• 230000003313 weakening effect Effects 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 229940072252 zestril Drugs 0.000 description 1
• 229940051223 zetia Drugs 0.000 description 1
• 229940072168 zocor Drugs 0.000 description 1